文献速递慢阻肺

pre-COPD评分预测新发COPD的开发与验证

Development and Validation of a Pre-COPD Score to Predict Incident COPD.
PubMed 文献 · Am J Respir Crit Care Med · 2026-11-06

研究基于CGPS(N=14,506)、CCHS(N=8,673)和COPDGene(N=2,982)中无气流阻塞的个体,在CGPS中开发pre-COPD评分(吸烟史≥10包年、当前吸烟、任何呼吸道症状、哮喘、BD前FEV1/FVC 0.70-0.75各1分,BD前FEV1<80%预计值4分),并在CCHS和COPDGene外部验证。随访5-10年,CGPS、CCHS和COPDGene分别有669例(4.6%)、685例(7.9%)和367例(12%)发生COPD。评分区分度良好,AUC分别为0.88、0.76和0.81,且与急性加重相关。

要点

  • pre-COPD评分可预测无气流阻塞个体新发COPD,区分度良好。
  • CGPS中10年COPD发病率低危1.5%、中危9.3%、高危24%、极高危42%。
  • 评分与急性加重相关,有助于识别高风险人群。

核心结论

  • pre-COPD评分可在三个风险特征不同的队列中有效预测COPD发病,并具有临床相关的区分度。

研究设计与样本

  • 研究纳入CGPS(N=14,506)、CCHS(N=8,673)和COPDGene(N=2,982)中无气流阻塞的个体。
  • 在CGPS中开发pre-COPD评分,并在CCHS和COPDGene中进行外部验证。
  • 随访5-10年,观察新发COPD(BD前FEV1/FVC<0.70且FEV1<80%预计值)。

主要发现

  • 随访期间,CGPS、CCHS和COPDGene分别有669例(4.6%)、685例(7.9%)和367例(12%)发生COPD。
  • CGPS中10年COPD发病率:低危1.5%、中危9.3%、高危24%、极高危42%。
  • CCHS中5年发病率:低危3.7%、中危7.3%、高危12%、极高危25%。
  • COPDGene中5年发病率:低危4.1%、中危5.3%、高危13%、极高危31%。
  • pre-COPD评分的AUC在CGPS为0.88、CCHS为0.76、COPDGene为0.81。

关键数值与推荐

  • pre-COPD评分赋值:吸烟史≥10包年、当前吸烟、任何呼吸道症状、哮喘、BD前FEV1/FVC 0.70-0.75各1分;BD前FEV1<80%预计值(PRISm)4分。

临床怎么用

  • pre-COPD评分可用于识别无气流阻塞但COPD发病风险高的个体,指导早期干预和随访。
  • 评分与急性加重相关,提示高风险患者可能需更密切监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: The ability to predict progression from a pre-disease state in chronic obstructive pulmonary disease (COPD), pre-COPD, to overt COPD remains limited. OBJECTIVE: To test the hypothesis that development of COPD can be predicted by characterizing pre-COPD and creating a simple pre-COPD score. METHODS: We identified individuals without airflow obstruction, defined as pre-bronchodilator (BD) forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC)≥0.70 and ≥lower limit of normal, from the Copenhagen General Population Study (CGPS)(N = 14,506), Copenhagen City Heart Study (CCHS)(N = 8673), and Genetic Epidemiology for COPD (COPDGene) Study(N = 2982). A pre-COPD score was developed in CGPS by assigning 1 point to each of smoking history≥10 pack-years, active smoking, any respiratory symptom, asthma, and pre-BD FEV1/FVC 0.70-0.75, and 4 points for pre-BD FEV1<80% predicted, indicating presence of Preserved Ratio Impaired Spirometry (PRISm), with external validation in CCHS and COPDGene. Participants were followed for 5-10 years for incident COPD, defined as pre-BD FEV1/FVC<0.70 and FEV1<80% predicted. MEASUREMENTS AND MAIN RESULTS: During follow-up, COPD developed in 669 individuals (4.6%) in CGPS, 685 (7.9%) in CCHS, and 367 (12%) in COPDGene. In CGPS, 10-year incidence was 1.5% in the low-risk, 9.3% in the intermediate-risk, 24% in the high-risk, and 42% in the very high-risk category. Corresponding 5-year incidences were 3.7%, 7.3%, 12%, and 25% in CCHS, and 4.1%, 5.3%, 13%, and 31% in COPDGene, respectively. The pre-COPD score demonstrated good discrimination with areas under curve of 0.88 in CGPS, 0.76 in CCHS, and 0.81 in COPDGene. The pre-COPD score was also associated with exacerbations. CONCLUSIONS: The pre-COPD score is useful in predicting the onset of COPD with clinically relevant discrimination in three cohorts with different risk profiles.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Çolak Y, Bhatt SP, Kinney GL, et al. Development and Validation of a Pre-COPD Score to Predict Incident COPD. Am J Respir Crit Care Med. 2026. PMID: 42993069. doi:10.1093/ajrccm/aamag599

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。